Systemic inflammation and arrhythmic risk: Lessons from rheumatoid arthritis

European Heart Journal

Volumn 38, Issue 22, 2017, Pages 1717-1727

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Arrhythmic risk; Atrial fibrillation; Cytokines; Rheumatoid arthritis; Sudden cardiac death; Systemic inflammation; Ventricular arrhythmias

Indexed keywords

ATRIAL FIBRILLATION; AUTONOMIC NEUROPATHY; CONGESTIVE HEART FAILURE; DISEASE ACTIVITY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SUDDEN CARDIAC DEATH; CARDIAC MUSCLE CELL; COMPLICATION; ELECTROCARDIOGRAPHY; EPIDEMIOLOGY; FEMALE; HEART INFARCTION; MALE; METABOLISM; MIDDLE AGED; MYOCARDITIS; PHYSIOLOGY; RISK FACTOR;

CYTOKINE;

ARRHYTHMIAS, CARDIAC; ARTHRITIS, RHEUMATOID; CYTOKINES; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCYTES, CARDIAC; RISK FACTORS;

EID: 85021648544     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw208     Document Type: Review

References (130)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
2. Klingenberg R, Lüscher TF. Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison. Eur Heart J 2015; 36: 3423-3425.
3. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008; 121: S9-14.
4. Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. AnnRheum Dis 2014; 73: 1797-1804.
5. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36: 482-489.
6. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121: S21-S31.
7. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70: 8-14.
8. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of selflimiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology 2010; 49: 528-535.
9. Mantel ä, Holmqvist M, Jernberg T, Wållberg-Jonsson S, Askling J. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J 2015; 36: 3413-3422.
10. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. A population-based cohort study. Arthritis Rheum 2005; 52: 402-411.
11. Ungprasert P, Srivali N, KittanamongkolchaiW. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 2015. doi: 10. 1111/1756-185X. 12820.
12. Tomaselli GF, Zipes DP. What causes sudden death in heart failure Circ Res 2004; 95: 754-763.
13. Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Heart Rhythm 2011; 8: 1963-1968.
14. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
15. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev 2014; 13: 936-944.
16. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Eng J Med 2001; 345: 1473-1482.
17. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int J Cardiol 2014; 177: 535-537.
18. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. AnnRheum Dis 2012; 71: 1524-1529.
19. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-1601.
20. Van Doornum S, Brand C, King B, Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2061-2068.
21. Van Doornum S, Bohensky M, Tacey MA, Brand CA, Sundararajan V, Wicks IP. Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease. Arthritis Res Ther 2015; 17: 38.
22. Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, Banks MJ, Kitas GD. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65: 348-353.
23. Mackey RH, Kuller LH, Deane KD, Walitt BT, Chang YF, Holers VM, Robinson WH, Tracy RP, Hlatky MA, Eaton CB, Liu S, Freiberg MS, Talabi MB, Schelbert EB, Moreland LW. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative. Arthritis Rheumatol 2015; 67: 2311-2322.
24. Desai SP, Januzzi JL, Pande AN, Pomerantsev EV, Resnic FS, Fossel A, Chibnik LB, Solomon DH. Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention. Semin Arthritis Rheum 2010; 40: 215-221.
25. Ben-Zvi I, Goldenberg I, Matetzky S, Grossman C, Elis A, Gavrielov-Yusim N, Livneh A. The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. Clin Rheumatol 2016; 35: 233-237.
26. Gö ldeli O, Dursun E, Komsuoglu B. Dispersion of ventricular repolarization: a new marker of ventricular arrhythmias in patients with rheumatoid arthritis. J Rheumatol 1998; 25: 447-450.
27. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, Barreca C, Galeazzi M, Laghi-Pasini F. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med 2013; 24: 368-374.
28. Cindas A, Gökçe-Kutsal Y, Tokgözoglu L, Karanfil A. QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol 2002; 31: 22-26.
29. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology 2003; 42: 292-297.
30. Pirildar T, Sekuri C, Utük O, Tezcan UK. QT dispersion in rheumatoid arthritis patients with and without Sjö gren's syndrome. Clin Rheumatol 2003; 22: 225-228.
31. Ahmad S, Garg S, Dhar M, Srivastava S, Biswas D, Barthwal SP, Shirazi N, Srivastava R. Predictors of atherosclerosis in rheumatoid arthritis. Vasa 2012; 41: 353-359.
32. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology 2014; 53: 131-137.
33. Acar GR, Akkoyun M, Nacar AB, Dirnak I, Yldrm Çetin G, Nur Yldrm M, Zencir C, Karaman K, Cetin M. Sayarloglu MEvaluation of Tp-e interval and Tp-e/ QT ratio in patients with rheumatoid arthritis. Turk Kardiyol Dern Ars 2014; 42: 29-34.
34. Chauhan K, Ackerman M, Crowson CS, Matteson EL, Gabriel SE. Populationbased study of QT interval prolongation in patients with rheumatoid arthritis. Clin Exp Rheumatol 2015; 33: 84-89.
35. Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol 2015; 42: 421-428.
36. Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F. Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis: Tocilizumab reduces QTc interval by controlling systemic inflammation. Arthritis Care Res 2015; 67: 332-339.
37. Adlan AM, Lip GY, Paton JF, Kitas GD, Fisher JP. Autonomic function and rheumatoid arthritis: a systematic review. Semin Arthritis Rheum 2014; 44: 283-304.
38. Stein PK, Bosner MS, Kleiger RE, Conger BM. Heart rate variability: a measure of cardiac autonomic tone. Am Heart J 1994; 127: 1376-1381.
39. Huikuri HV, Stein PK. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis 2013; 56: 153-159.
40. Evrengül H, Dursunoglu D, Cobankara V, Polat B, Seleci D, Kabukçu S, Kaftan A, Semiz E, Kilic M. Heart rate variability in patients with rheumatoid arthritis. Rheumatol Int 2004; 24: 198-202.
41. Anichkov DA, Shostak NA, Ivanov DS. Heart rate variability is related to disease activity and smoking in rheumatoid arthritis patients. Int J Clin Pract 2007; 61: 777-783.
42. Kamal A. Assessment of autonomic function in patients with rheumatoid arthritis using spectral analysis and approximate entropy method. Neurosciences 2007; 12: 136-139.
43. Vlcek M, Rovensky J, Blazicek P, Radikova Z, Penesova A, Kerlik J, Kvetnanský R, Imrich R. Sympathetic nervous system response to orthostatic stress in female patients with rheumatoid arthritis. Ann NY Acad Sci 2008; 1148: 556-561.
44. Aydemir M, Yazisiz V, Basarici I, Avci AB, Erbasan F, Belgi A, Terzioglu E. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus. Lupus 2010; 19: 255-261.
45. Milovanovic B, Stojanovic L, Milicevik N, Vasic K, Bjelakovic B, Krotin M. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk. Srp Arh Celok Lek 2010; 138: 26-32.
46. Bruchfeld A, Goldstein RS, Chavan S, Patel NB, Rosas-Ballina M, Kohn N, Qureshi AR, Tracey KJ. Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med 2010; 268: 94-101.
47. Yadav RK, Gupta R, Deepak KK. A pilot study on short term heart rate variability & its correlation with disease activity in Indian patients with rheumatoid arthritis. Indian J Med Res 2012; 136: 593-598.
48. Vlcek M, Rovensky J, Eisenhofer G, Radikova Z, Penesova A, Kerlik J, Imrich R. Autonomic nervous system function in rheumatoid arthritis. Cell Mol Neurobiol 2012; 32: 897-901.
49. Janse van Rensburg DC, Ker JA, Grant CC, Fletcher L. Autonomic impairment in rheumatoid arthritis. Int J Rheum Dis 2012; 15: 419-426.
50. Kim HA, Jeon JY, Koh BR, Park SB, Suh CH. Salivary cortisol levels, but not salivary a-amylase levels, are elevated in patients with rheumatoid arthritis irrespective of depression. Int J Rheum Dis 2016; 19: 172-177.
51. Lazzerini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, Bisogno S, Guideri F, Galeazzi M, Pasini FL. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol 2008; 35: 1958-1965.
52. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008; 372: 750-763.
53. Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004; 19: 2-11.
54. Di Lorenzo M, Schiavo B. Rheumatoid heart: report of a case with endomyocardial injury and severe arrhythmias. G Ital Cardiol 1978; 8: 886-891.
55. Tsuji M, Dowaki M, Yamada A, Nakura Y, Takahashi S, Hatano M, Sawada S, Nishinarita S, Ishikawa H. A case of anti-RNP antibody positive malignant rheumatoid arthritis with pulmonary hypertension. Nihon Naika Gakkai Zasshi 1991; 80: 1673-1675.
56. Lai D, Brown G, MacDonald I. Clarithromycin-induced prolonged QT syndrome. Can J Hosp Pharm 1996; 49: 33-35.
57. Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861-863.
58. Bruggisser M, Ratz Bravo A, Brodmer M. Medication associated long QT syndrome. Praxis 2009; 98: 1409-1415.
59. Vilaseca-Corbera M, Vázquez-Oliva G, Campoamor-Cela C, Zamora-Cervantes A, Bassanyanes-Vilarrasa J, Massa-Puig R. Extreme QT interval prolongation and helicoid ventricular tachycardia (torsade de pointes) in non-ST-elevation acute coronary syndrome. Rev Esp Cardiol 2012; 65: 294-296.
60. ViewegWV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis 2013; 1: 121-138.
61. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, May J. Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics 2015; 56: 36-43.
62. Lazzerini PE, Yue Y, Srivastava U, Fabris F, Capecchi PL, Bertolozzi I, Bacarelli MR, Morozzi G, Acampa M, Natale M, El-Sherif N, Laghi-Pasini F, Boutjdir M. Arrhythmogenicity of anti-Ro/SSA antibodies in patients with Torsades de Pointes. Circ Arrhythm Electrophysiol 2016; 9. doi: 10. 1161/CIRCEP. 115. 003419.
63. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med 2015; 2: 26. doi: 10. 3389/ fcvm. 2015. 00026.
64. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998; 98: 1928-1936.
65. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, McTiernan CF, Feldman AM, Salama G. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H431-H441.
66. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2006; 290: H2098-H2107.
67. Kawada H, Niwano S, Niwano H, Yumoto Y, Wakisaka Y, Yuge M, Kawahara K, Izumi T. Tumor necrosis factor-alpha downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. Circ J 2006; 70: 605-609.
68. Fernández-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. TNF-alpha downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Am J Physiol Heart Circ Physiol 2007; 293: H238-H245.
69. Panama BK, Latour-Villamil D, Farman GP, Zhao D, Bolz SS, Kirshenbaum LA, Backx PH. Nuclear factor kappaB downregulates the transient outward potassium current I (to, f) through control of KChIP2 expression. Circ Res 2011; 108: 537-543.
70. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z. Impairment of HERG K (+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem 2004; 279: 13289-13292.
71. Li YH, Rozanski GJ. Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res 1993; 27: 525-530.
72. Hagiwara Y, Miyoshi S, Fukuda K, Nishiyama N, Ikegami Y, Tanimoto K, Murata M, Takahashi E, Shimoda K, Hirano T, Mitamura H, Ogawa S. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2 + ]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 2007; 43: 710-716.
73. Elenkov IJ, Wilder RL, Chrousos GP, Vizi S. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
74. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-859.
75. Wu CT, Nattel S. Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies. J Physiol 2012; 590: 1311-1312.
76. De Jesus NM, Wang L, Herren AW, Wang J, Shenasa F, Bers DM, Lindsey ML, Ripplinger CM. Atherosclerosis exacerbates arrhythmia after myocardial infarction: role of myocardial inflammation. Heart Rhythm 2015; 12: 169-178.
77. Yu X, Patterson E, Huang S, Garrett MW, Kem DC. Tumor necrosis factor alpha, rapid ventricular tachyarrhythmias, and infarct size in canine models of myocardial infarction. J Cardiovasc Pharmacol 2005; 45: 153-159.
78. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-1078.
79. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60: 2263-2270.
80. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, Torp-Pedersen C, Hansen PR. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344: e1257.
81. Kim SC, Liu J, Solomon DH. The risk of atrial fibrillation in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73: 1091-1095.
82. Bacani AK, Crowson CS, Roger VL, Gabriel SE, Matteson EL. Increased incidence of atrial fibrillation in patients with rheumatoid arthritis. Biomed Res Int 2015; 2015: 809514.
83. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin 2010; 6: 187-200.
84. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007; 87: 425-456.
85. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, Hippeläinen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 2007; 297: 1562-1567.
86. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12: 230-243.
87. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 2005; 289: H1456-H1467.
88. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 2004; 64: 507-515.
89. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, Moe KT. Role of tumor necrosis factor-a in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J 2013; 77: 1171-1179.
90. van Nieuwenhoven FA, Hemmings KE, Porter KE, Turner NA. Combined effects of interleukin-1a and transforming growth factor-b1 on modulation of human cardiac fibroblast function. Matrix Biol 2013; 32: 399-406.
91. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol 2007; 292: H1561-H1567.
92. Baum JR, Long B, Cabo C, Duffy HS. Myofibroblasts cause heterogeneous Cx43 reduction and are unlikely to be coupled to myocytes in the healing canine infarct. Am J Physiol Heart Circ Physiol 2012; 302: H790-H800.
93. Zarain-Herzberg A, Estrada-Avilés R, Fragoso-Medina J. Regulation of sarco (endo)plasmic reticulum Ca2+-ATPase and calsequestrin gene expression in the heart. Can J Physiol Pharmacol 2012; 90: 1017-1028.
94. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 2010; 47: 378-386.
95. Mitrokhin VM, Mladenov MI, Kamkin AG. Effects of interleukin-6 on the bioelectric activity of rat atrial tissue under normal conditions and during gradual stretching. Immunobiology 2015; 220: 1107-1112.
96. Mitrokhin VM, Mladenov MI, Kamkin AG. IL-1 provokes electrical abnormalities in rat atrial myocardium. Int Immunopharmacol 2015; 28: 780-784.
97. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73.
98. Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6: 159-165.
99. Yavuzkir M, Ozturk A, Dagli N, Koca S, Karaca I, Balin M, Işik A. Effect of ongoing inflammation in rheumatoid arthritis on P-wave dispersion. J Int Med Res 2007; 35: 796-802.
100. Guler H, Seyfeli E, Sahin G, Duru M, Akgul F, Saglam H, Yalcin F. P wave dispersion in patients with rheumatoid arthritis: its relation with clinical and echocardiographic parameters. Rheumatol Int 2007; 27: 813-818.
101. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, nonsteroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
102. Syngle A, Verma I, Krishan P, Garg N, Syngle V. Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study. Clin Rheumatol 2015; 34: 1233-1241.
103. Syngle A, Verma I, Krishan P. Interleukin-6 blockade improves autonomic dysfunction in rheumatoid arthritis. Acta Reumatol Port 2015; 40: 85-88.
104. Meek IL, Vonkeman HE, van de Laar MA. Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord 2014; 15: 142.
105. Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF. Increased risk of arrhythmia in patients with psoriatic disease: a nationwide population-based matched cohort study. J Am Acad Dermatol 2015; 73: 429-438.
106. Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33: 2054-2064.
107. Keller JJ, Hsu JL, Lin SM, Chou CC, Wang LH, Wang J, Bai CH, Chiou HY. Increased risk of stroke among patients with ankylosing spondylitis: a populationbased matched-cohort study. Rheumatol Int 2014; 34: 255-263.
108. Kristensen SL, Lindhardsen J, Ahlehoff O, Erichsen R, Lamberts M, Khalid U, Torp-Pedersen C, Nielsen OH, Gislason GH, Hansen PR. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. Europace 2014; 16: 477-484.
109. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-1264.
110. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-1189.
111. Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harlé JR, Jougla E, Chiche L. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol 2014; 66: 2503-2511.
112. Simsek H, Sahin M, Akyol A, Akdag S, Ozkol HU, Gumrukcuoglu HA, Gunes Y. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. ScientificWorldJournal 2013; 2013: 901215.
113. Bacaksiz A, Erdogan E, Tasal A, Vatankulu MA, Kul S, Sevgili E, Ertas G, Dizman D, Onsun N, Uysal O. Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris. Ups J Med Sci 2013; 118: 35-41.
114. Borman P, Gokoglu F, Kocaoglu S, Yorgancioglu ZR. The autonomic dysfunction in patients with ankylosing spondylitis: a clinical and electrophysiological study. Clin Rheumatol 2008; 27: 1267-1273.
115. Acar G, Yorgun H, Inci MF, Akkoyun M, Bakan B, Nacar AB, Dirnak I, Cetin GY, Bozoglan O. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with ankylosing spondylitis. Mod Rheumatol 2014; 24: 327-330.
116. Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G, Galeazzi M, Marcolongo R, Laghi-Pasini F. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 2004; 50: 1248-1252.
117. Dogdu O, Yarlioglues M, Kaya MG, Ardic I, Kilinc Y, Elcik D, Kelesoglu S, Akpek M, Sahin O, Cosgun S, Oguzhan N, Oguzhan A. Assessment of atrial conduction time in patients with systemic lupus erythematosus. J Investig Med 2011; 59: 281-286.
118. Curione M, Aratari A, Amato S, Colotto M, Barbato M, Leone S, Tego A, Panetti D, Parlapiano C. A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement. Intern Emerg Med 2010; 5: 307-310.
119. Dogan Y, Soylu A, Eren GA, Poturoglu S, Dolapcioglu C, Sonmez K, Duman H, Sevindir I. Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int J Med Sci 2011; 8: 540-546.
120. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2259.
121. Empana JP, Jouven X, Canoü-Poitrine F, Luc G, Tafflet M, Haas B, Arveiler D, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol 2010; 30: 2047-2052.
122. Hussein AA, Gottdiener JS, Bartz TM, Sotoodehnia N, DeFilippi C, See V, Deo R, Siscovick D, Stein PK, Lloyd-Jones D. Inflammation and sudden cardiac death in a community-based population of older adults: the Cardiovascular Health Study. Heart Rhythm 2013; 10: 1425-1432.
123. Penã JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531-537.
124. Kim E, Joo S, Kim J, Ahn J, Kim J, Kimm K, Shin C. Association between C-reactive protein and QTc interval in middle-aged men and women. Eur J Epidemiol 2006; 21: 653-659.
125. Medenwald D, Kors JA, Loppnow H, Thiery J, Kluttig A, Nuding S, Tiller D, Greiser KH, Werdan K, Haerting J. Inflammation and prolonged QT time: results from the Cardiovascular Disease, Living and Ageing in Halle (CARLA) study. PLoS ONE 2014; 9: e95994.
126. Sajadieh A, NielsenOW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004; 25: 363-370.
127. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007; 13: 178-184.
128. Medenwald D, Dietz S, Tiller D, Kluttig A, Greiser KH, Loppnow H, Thiery J, Nuding S, Russ M, Fahrig A, Haerting J, Werdan K. Inflammation and echocardiographic parameters of ventricular hypertrophy in a cohort with preserved cardiac function. Open Heart 2014; 1: e000004.
129. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782-1791.
130. Couzin-Frankel J. Cardiovascular disease. Massive trials to test inflammation hypothesis. Science 2012; 337: 1158.